ABBV-184

ABBV-184 is a first-in-class, investigational bispecific protein therapeutic developed by AbbVie. It is composed of a soluble T-cell receptor (TCR) arm that specifically binds to a survivin-derived peptide presented by the class I MHC allele HLA-A2:01 on tumor cells, and an anti-CD3 moiety that engages CD3 on T cells. This design enables redirection of T cells to recognize and kill survivin-expressing tumor cells. Survivin (BIRC5) is broadly expressed in both solid tumors and hematologic malignancies but has limited expression in normal tissues, making it an attractive target for cancer therapy. Preclinical studies demonstrated that ABBV-184 induces T-cell activation, proliferation, and cytotoxicity against HLA-A2-positive acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC) cell lines. It was evaluated in phase 1 clinical trials as monotherapy in patients with relapsed/refractory AML or NSCLC who are HLA-A2 positive, but development has since been discontinued.

Other names

anti-survivin T-cell receptor/anti-CD3 bispecific therapeutic